A clinical questing examination to verify vasculo-protective effect of azilsartan treatment in the uncontrolled hypertensive patients with diabetes mellitus.

A clinical questing examination to verify vasculo-protective effect of azilsartan treatment in the uncontrolled hypertensive patients with diabetes mellitus. - A clinical questing examination to verify vasculo-protective effect of azilsartan treatment in the uncontrolled hypertensive patients with diabetes mellitus.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011892

Enrollment

Registered

2013-09-27

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese hypertensive patients with diabetes mellitus.

Interventions

This study is a clinical questing trial. The entry period of this study is one years. Study subjects are uncontrolled hypertensive patients with Diabetes. (If the patients have already been treating w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects enrolled in the present study are hypertensive out-patients with diabetes, who fulfill the following criteria; 1) Mild or moderate hypertension defined as the blood pressure from 130 / 80mmHg to 180 / 110 mmHg. 2) Do not taking of direct renin inhibitor such as aliskiren, for at least six months. 3) The participation agreement of this study is obtained.

Exclusion criteria

Exclusion criteria: 1) Corresponding to the GFR < 30 ml/min/1.73m2, or receiving continuous dialysis. 2) Woman who has pregnancy or possibility of pregnancy and suckling. 3) To have other serious and active diseases such as severe hyperglycemia (HbA1c > 10%), liver dysfunction, cardiovascular disease, malignancies and so on). 4) Severe hypertensive subjects (> 180 / 110 mmHg). 5) The patient that corresponds to taking of Aliskiren treatment. 6) The patient with renal artery stenosis, 7) The patient whose serum potassium level is more than 5.5, 8) Patient from whom physician in charge of treatment judged this study participation to be improper.

Design outcomes

Primary

Measure	Time frame
percentage change of vascular resiliency.	—

Secondary

Measure	Time frame
percentage changes of blood pressure	—

Countries

Japan

Contacts

Public ContactSusumu Ogawa

Tohoku University Hospital Division of Nephrology, Endocrinology and Hypertension

ogawa-s@hosp.tohoku.ac.jp022-717-7163

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026